New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 24, 2014
08:43 EDTVRTXVertex shares should be owned ahead of data, says JMP Securities
JMP Securities expects Phase 3 data for Kalydeco in combination with corrector lumacaftor, expected to be announced mid-year, to be positive. It recommends that ivnestors own the stock ahead of the data. The firm notes that Vertex received a label expansion for Kalydeco fro mthe FDA, and it reiterates a $115 price target and Outperform rating on the stock.
News For VRTX From The Last 14 Days
Check below for free stories on VRTX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for VRTX

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use